Anthem Biosciences IPO
GMP, Subscription, Price, Dates & Financial Details

Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO) based in India. The company offers fully integrated services across the drug lifecycle—from discovery to development and commercial manufacturing—serving global pharmaceutical and biotech companies.

Key Business Segments:

1. CRDMO Services:
   • Supports New Chemical Entities (NCEs) and New Biological Entities (NBEs).
   • Offers services from target identification to clinical trials (Phase I–III) and commercial manufacturing.
   • Capabilities include RNAi, Antibody-Drug Conjugates (ADCs), peptides, lipids, oligonucleotides, flow chemistry, enzymatic processes, and fermentation.
2. Specialty Ingredients:
   • Manufactures fermentation-based Active Pharmaceutical Ingredients (APIs) like probiotics, enzymes, peptides, vitamin analogues, and biosimilars.
   • Serves both regulated (U.S., Europe) and semi-regulated markets (Asia, Latin America, Middle East).

Operational Highlights (as of September 30, 2024):

• 196 active projects, including:
  • 170 Discovery (284 molecules),
  • 132 Early Phase,
  • 16 Late Phase (10 molecules),
  • 13 Commercial Manufacturing (10 commercial molecules).
• Supported 10 commercial molecules from discovery to manufacturing.
• Completed over 8,000 unique customer projects for more than 675 clients.
• Top 5 commercial molecules (for 3 large pharma clients) had a US$9.0 billion market in 2023, projected to grow to US$20 billion by 2028.

Customer Base:

• Over 550 customers globally (as of March 31, 2024), across 44+ countries.
• Includes small biotech, mid-size, and large pharma companies.
• 3 large pharma companies contributed to top 5 commercialized molecules in FY24.

Innovation & Capabilities:

• Among the fastest-growing CRDMOs in India, achieving ₹10,000 million in revenue within 14 years (by FY21).
• First in India to:
  • Develop ADCs (2016),
  • Work on monoclonal antibody payloads (2019),
  • Develop glycolipid-based RNAi delivery.
• Invested in:
  • Solid-state peptide synthesis lab (2016),
  • Large-scale fermentation (2017),
  • cGMP continuous flow manufacturing (2022),
  • Oligonucleotide synthesis lab (2023).
• Strong emphasis on green chemistry (biotransformation, flow chemistry).

Intellectual Property & Talent:

• Holds 8 patents (1 India, 7 overseas), with 24 global applications pending.
• Workforce of 600 employees, including chemists, biologists, engineers, and non-clinical research experts.

Competitive Strengths:

• End-to-end capabilities in both small molecules and biologics.
• Technological leadership in advanced modalities and green manufacturing.
• Long-standing relationships with a diversified customer base.
• Recognized for highest revenue growth in FY23–FY24 among peers (F&S Report).